10-KPeriod: FY2017

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2017

Filed February 16, 2018For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported strong performance in its 2017 10-K filing, demonstrating robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. The company's strategy of providing integrated diagnostic solutions and leveraging recurring revenue streams from consumables and services continues to be effective. Significant investments in research and development, alongside a focus on innovation, position IDEXX for continued leadership in the veterinary diagnostics market. The company's financial health appears solid, with positive operating income and a healthy cash position. While facing competitive pressures and global economic uncertainties, IDEXX's diversified business model across veterinary, water, and livestock sectors, along with its strategic focus on technological advancements and customer value, provides a strong foundation for future growth. The filing also highlights the company's proactive approach to adopting new accounting standards and managing market risks, including currency fluctuations.

Financial Highlights

54 data points
Beta

Revenue

$1.97B

55.7% Gross Margin

Net Income

$263.14M

13.4% Net Margin

EPS (Diluted)

$2.94

Total Assets

$1.71B

Cash & Equivalents

$187.68M

Free Cash Flow

$298.89M

Financial Statements
Beta
Revenue$1.97B
Cost of Revenue$871.68M
Gross Profit$1.10B
R&D Expenses$109.18M
Operating Income$413.03M
Interest Expense$37.23M
Net Income$263.14M
EPS (Basic)$3.00
EPS (Diluted)$2.94
Shares Outstanding (Basic)87.77M
Shares Outstanding (Diluted)89.57M

Key Highlights

  • 1Strong Revenue Growth: The company reported a 10.9% increase in total revenue for 2017 compared to 2016, reaching $1.97 billion, driven largely by its Companion Animal Group (CAG).
  • 2CAG Segment Strength: The CAG segment saw an 11.9% revenue increase, with CAG Diagnostics recurring revenue (consumables, services) showing a particularly strong 13.3% growth.
  • 3Focus on Recurring Revenue: Recurring diagnostic revenue, a key driver of profitability, accounted for approximately 74% of consolidated revenue in 2017.
  • 4Investment in Innovation: Research and development expenses increased by 8.0% to $109.2 million, reflecting continued investment in new products and services.
  • 5Expanded Instrument Placements: The company saw continued growth in its installed base of key instruments like Catalyst analyzers and ProCyte Dx hematology analyzers.
  • 6Strategic Shift in Instrument Placements: IDEXX is focusing on long-term economic value through customer commitment programs and reagent rentals, which shifts revenue recognition from upfront instrument sales to recurring consumable sales.
  • 7Successful International Expansion: International revenue grew by 11.6%, with strong organic growth in Europe and Asia Pacific, indicating successful global market penetration.

Frequently Asked Questions

IDEXX operates through three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD). The CAG segment, which includes diagnostics and information technology for veterinary practices, is the largest and fastest-growing, with revenue up 11.9% in 2017. The Water segment grew 10.4%, and the LPD segment showed a modest 1.6% increase.

Growth in CAG is primarily driven by recurring diagnostic revenue, which includes IDEXX VetLab consumables, rapid assay products, and reference laboratory diagnostic and consulting services. This segment saw a 13.3% increase in recurring revenue, fueled by higher sales volumes and, in some areas, price increases, supported by strong customer adoption of their integrated diagnostic technologies and expanded test menus.

International revenue accounted for approximately 39% of total revenue in 2017, with strong organic growth observed in Europe and Asia Pacific. The company actively manages foreign currency risks through hedging activities and by denominating a significant portion of its operations and supply contracts in U.S. dollars. While a strengthening U.S. dollar can negatively impact reported international results, IDEXX's hedging strategies aim to mitigate these effects.

IDEXX views R&D as crucial for maintaining its competitive edge. In 2017, R&D expenses were $109.2 million, representing 5.5% of revenue. This investment supports the development of new diagnostic technologies, analyzers, and software solutions designed to enhance veterinary care and practice efficiency, such as the recently launched Catalyst SDMA Test.